TP53 and thyroid cancer: Review articles discussing these models (Table 2, Fig. 3) have already been published, which include BrafV600E knock-in mice crossed with cooperating alterations commonly found in advanced thyroid cancer patients whose tumors are driven by BRAFV600E (e.g., TERT promoter mutations, TP53 and PI3K pathway genes alterations) (13, 14, 26, 27).